Next steps in targeting the CNS with AAV-driven gene therapy

Cell & Gene Therapy Insights 2020; 6(4), 577–582

10.18609/cgti.2020.067 Q Can

Published: 14 May 2020
Bruce Goldsmith

Bruce Goldsmith is Passage Bio’s CEO and President, and he also serves on its Board of Directors. Dr Goldsmith has extensive experience in the biopharma and biotechnology industries through the many roles he has held across the research and corporate spectrum. Prior to Passage, Dr Goldsmith was a Venture Partner at Deerfield Ventures and Interim CEO of Civetta Therapeutics.